GSK plc (NYSE:GSK – Get Rating) was the target of some unusual options trading activity on Tuesday. Traders purchased 21,713 call options on the stock. This represents an increase of 86% compared to the average daily volume of 11,681 call options.
GSK Stock Performance
GSK stock opened at $33.85 on Wednesday. GSK has a 1-year low of $28.47 and a 1-year high of $46.97. The firm has a market cap of $68.84 billion, a P/E ratio of 4.15, a P/E/G ratio of 1.16 and a beta of 0.67. The firm has a 50-day moving average of $31.40 and a 200-day moving average of $37.15. The company has a current ratio of 0.97, a quick ratio of 0.74 and a debt-to-equity ratio of 2.22.
GSK Cuts Dividend
The business also recently declared a quarterly dividend, which will be paid on Thursday, January 12th. Investors of record on Friday, November 18th will be paid a $0.3695 dividend. This represents a $1.48 dividend on an annualized basis and a yield of 4.37%. The ex-dividend date of this dividend is Thursday, November 17th. GSK’s payout ratio is currently 15.20%.
Hedge Funds Weigh In On GSK
Analyst Ratings Changes
Several analysts have issued reports on GSK shares. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 11th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Thursday, September 8th. JPMorgan Chase & Co. cut their price target on shares of GSK from GBX 1,900 ($22.47) to GBX 1,600 ($18.92) in a research report on Tuesday, November 8th. Oddo Bhf upgraded shares of GSK from a “neutral” rating to an “outperform” rating in a research report on Thursday, September 29th. Finally, Credit Suisse Group upgraded shares of GSK from an “underperform” rating to a “neutral” rating in a report on Thursday, September 15th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $1,608.33.
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Get a free copy of the StockNews.com research report on GSK (GSK)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.